PTEN and melanoma: Recent literature suggests that PTEN-deficient tumors show increased expression of immunosuppressive cytokines and genetic silencing of PTEN expression in melanoma cells attenuated anti-tumorigenic T cell responses in vivo, leading to resistance to PD-1 immune checkpoint blockade [62].